Dr. Christopher J. Sayed shares insights on the growing emphasis on personalized care for hidradenitis suppurativa.

Hidradenitis suppurativa treatment experiences vary widely among patients; a new study highlights the need for personalised care and shared decision-making.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Study authors examined the relationship between the use of combined oral contraceptives and the onset of hidradenitis suppurativa.

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

A panelist discusses how clinicians should systematically adopt evidence-based hidradenitis suppurativa (HS) guidelines while maintaining flexibility to tailor treatments to individual patient needs, ...

—Megan Rogge, MD, of McGovern Medical School, UTHealth Houston, explains the need for specific biomarkers in HS, noting that ones like ESR and CRP, while often elevated in these patients, are ...

Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates ...

—Cytokines, chemokines, inflammatory nodules, sinus tracts,and more: Dr. Megan Rogge of McGovern Medical School, UTHealth Houston, discusses the complicated pathophysiology of hidradenitis ...

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...